6:27 PM
 | 
Apr 19, 2010
 |  BC Extra  |  Clinical News

Gilead stops HCV trial

Gilead Sciences Inc. (NASDAQ:GILD) said late Monday that it will stop a Phase II trial of...

Read the full 62 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >